Zepp Health Corporation Announces Receipt of NYSE Non-compliance Letter Regarding ADS Trading Price

Rhea-AI Summary

Zepp Health received a letter from the NYSE stating that it is below compliance standards due to the trading price of its American depositary shares (ADSs). The company has six months to regain compliance by maintaining a closing share price of at least US$1.00 per ADS over a consecutive 30 trading-day period. If not attained, the NYSE may commence suspension and delisting procedures. Zepp Health intends to cure the deficiency and is exploring options, including a reverse share split if needed.

Positive

• None.

Negative

• Zepp Health is facing the risk of suspension and delisting from the NYSE if it fails to meet the minimum share price requirement within the given timeframe.

• The potential need for a reverse share split, subject to board and shareholder approval, may indicate financial challenges within the company.

MILPITAS, Calif., May 10, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange (the "NYSE") dated April 30, 2024, notifying Zepp that it is below compliance standards due to the trading price of Zepp's American depositary shares (the "ADSs").

Pursuant to Section 802.01C of the NYSE's Listed Company Manual, a company will be considered to be below compliance standards if the average closing price of its security as reported on the consolidated tape is less than US$1.00 over a consecutive 30 trading-day period. The Company has six months (the "Cure Period") following receipt of the notice to regain compliance with the minimum share price requirement. The Company can regain compliance at any time during the Cure Period if on the last trading day of any calendar month during the Cure Period the Company has a closing share price of at least US$1.00 per ADS and an average closing share price of at least US$1.00 per ADS over the 30 trading-day period ending on the last trading day of that month. In the event that at the expiration of the six-month Cure Period, both a US$1.00 per ADS closing share price on the last trading day of the Cure Period and a US$1.00 per ADS average closing share price over the 30 trading-day period ending on the last trading day of the Cure Period are not attained, the NYSE will commence suspension and delisting procedures.

Zepp Health has advised the NYSE of its intention to cure the deficiency within the applicable cure period and is considering all available options in this regard, which may include, if necessary, effecting a reverse share split, subject to board and shareholder approval.

The NYSE notice has no immediate effect on the listing of the Company's ordinary shares on the NYSE, subject to the Company's compliance with the NYSE's other continued listing requirements, and does not affect the Company's ongoing business operations or its reporting obligations under the rules of the U.S. Securities and Exchange Commission.

About Zepp Health Corporation

Zepp Health Corporation (NYSE: ZEPP) is a global smart wearable and health technology leader, empowering users to live their healthiest lives by optimizing their health, fitness, and wellness journeys through its leading consumer brands, Amazfit, Zepp Clarity and Zepp Aura. Powered by its proprietary Zepp Digital Management Platform, which includes the Zepp OS, AI chips, biometric sensors and data algorithms, Zepp delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. To date, Zepp has shipped over 200 million units, and its products are available in more than 90 countries and regions. Founded in 2013 as Huami Corp., the Company changed its name to Zepp Health Corporation in February 2021 to emphasize its health focus with a name that resonates across languages and cultures globally. Zepp has team members and offices across North America, Europe, Middle East, Africa and Asia Pacific regions.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the cooperation with Xiaomi, the recognition of the Company's self-branded products; the Company's growth strategies; trends and competition in global wearable technology market; changes in the Company's revenues and certain cost or expense accounting policies; governmental policies relating to the Company's industry and general economic conditions in China and the global. Further information regarding these and other risks is included in the Company's filings with the United States Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

In China:
Zepp Health Corporation
Grace Yujia Zhang
Email: ir@zepp.com 

Piacente Financial Communications
Tel: +86-10-6508-0677
Email: zepp@tpg-ir.com 

 

View original content:https://www.prnewswire.com/news-releases/zepp-health-corporation-announces-receipt-of-nyse-non-compliance-letter-regarding-ads-trading-price-302142206.html

SOURCE Zepp Health Corp.

FAQ

What is the reason for Zepp Health receiving a letter from the NYSE?

Zepp Health received a letter from the NYSE because it is below compliance standards due to the trading price of its American depositary shares (ADSs).

What is the minimum share price requirement set by the NYSE for compliance standards?

The NYSE requires a company to maintain a closing share price of at least US$1.00 per ADS over a consecutive 30 trading-day period to meet compliance standards.

What happens if Zepp Health fails to meet the minimum share price requirement within the cure period?

If Zepp Health fails to attain a US$1.00 per ADS closing share price and an average closing share price of at least US$1.00 per ADS over the 30 trading-day period, the NYSE may commence suspension and delisting procedures.

What actions is Zepp Health considering to regain compliance with the NYSE standards?

Zepp Health is considering various options to regain compliance, including potentially effecting a reverse share split, subject to board and shareholder approval.

Will the NYSE notice affect Zepp Health 's business operations or listing of ordinary shares on the NYSE?

The NYSE notice does not immediately impact the listing of Zepp Health 's ordinary shares on the NYSE, as long as the company complies with other listing requirements. It also does not affect the company's ongoing business operations or reporting obligations under the rules of the U.S. Securities and Exchange Commission.